



2nd December 2024

Stock Code BSE: 500696

NSE: HINDUNILVR

ISIN: INE030A01027

BSE Limited,
Corporate Relationship Department,
2nd Floor, New Trading Wing,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Ltd
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra – Kurla Complex,
Bandra (E),
Mumbai – 400 051

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is further to our letter dated 14th October 2024, intimating about filing of an appeal, with Commissioner of Income-tax (Appeals), Mumbai [CIT(A)], challenging the Assessment Order and the consequential Notice of Demand by the Income Tax Authorities whereby a demand of INR 962.75 Crores (including interest of INR 329.33 Crores) was raised on the Company. The Notice of Demand was raised on account of non-deduction of TDS as per provisions of Income Tax Act, 1961 while making remittance of INR 3,045 Crores (EUR 375.6 million) for payment towards acquisition of India HFD IPR from GlaxoSmithKline 'GSK' Group entities. Further, we had also intimated about the filing of application(s) with the Assessing Officer for stay of demand and to keep the penalty proceedings in abeyance.

Pursuant to the provisions of Regulation 30(7) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 (Listing Regulations), this is to inform that in view of the submission made by the Company, the Assessing Officer vide its Order dated 6th November 2024, directed the Company to make payment of 20 per cent of the total outstanding demand of INR 962.75 Crores on or before 30th November 2024 and kept the recovery proceedings in abeyance for the balance amount of the demand. The Company has made payment of INR 192.55 Crores on 28th November 2024 in compliance with the aforesaid direction. The payment was made pursuant to receipt of aforesaid amount under an indemnification claim as per the relevant Sale and Purchase Agreement and hence, doesn't have any financial implications at this stage.

Hindustan Unilever Limited,
Unilever House,
B D Sawant Marg, Chakala,
Andheri East, Mumbai 400 099

Tel: +91 (22) 50433000 | Web: www.hul.co.in | CIN: L15140MH1933PLC002030



Hindustan Unilever Limited

Please take the above information on record.

Thanking You.

Yours faithfully,

For Hindustan Unilever Limited

Dev Bajpai

**Executive Director, Legal & Corporate Affairs
and Company Secretary**

DIN:00050516 / FCS No: 3354